Accessibility navigation

Application of platelet-rich plasma as a stem cell treatment - an attempt to clarify a common public misconception

Fareez, I. M., Liew, F. F., Widera, D. ORCID:, Mayeen, N. F., Mawya, J., Abu Kasim, N. H. and Haque, N. (2023) Application of platelet-rich plasma as a stem cell treatment - an attempt to clarify a common public misconception. Current Molecular Medicine, 23. ISSN 1875-5666

[img] Text - Accepted Version
· Restricted to Repository staff only until 11 May 2024.


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.2174/1566524023666230511152646


In recent years, there has been a significant increase in the practice of regenerative medicine by health practitioners and direct-to-consumer businesses globally. Among different tools of regenerative medicine, platelet-rich plasma (PRP) and stem cell-based therapies have received considerable attention. The use of PRP, in particular, has gained popularity due to its easy access, simple processing techniques, and regenerative potential. However, it is important to address a common misconception amongst the general public equating to PRP and stem cells due to the demonstrated efficacy of PRP in treating musculoskeletal and dermatological disorders. Notably, PRP promotes regeneration by providing growth factors or other paracrine factors only. Therefore, it cannot replenish or replace the lost cells in conditions where a large number of cells are required to regenerate tissues and/or organs. In such cases, cell-based therapies are the preferred option. Additionally, other tools of regenerative medicine, such as bioprinting, organoids, and mechanobiology also rely on stem cells for their success. Hence, healthcare and commercial entities offering direct-to-customer regenerative therapies should not mislead the public by claiming that the application of PRP is a stem cell-based therapy. Furthermore, it is important for regulatory bodies to strictly monitor these profit-driven entities to prevent them from providing unregulated regenerative treatments and services that claim a broad variety of benefits with little proof of efficacy, safety concerns, and obscure scientific justification.

Item Type:Article
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:112019
Uncontrolled Keywords:Molecular Biology, Molecular Medicine, General Medicine, Biochemistry
Publisher:Bentham Science Publishers

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation